[{"id":"62adebca-4b95-438d-afa0-1e8661c4fb8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05262530","created_at":"2022-03-02T16:52:30.929Z","updated_at":"2025-02-25T16:26:48.535Z","phase":"Phase 1/2","brief_title":"Safety and Preliminary Efficacy Trial of BNT142 in Patients with CLDN6-positive Solid Tumors","source_id_and_acronym":"NCT05262530","lead_sponsor":"BioNTech SE","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 positive","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT142"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 03/28/2022","start_date":" 03/28/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-31"},{"id":"d92c9e11-bf8f-4526-95a3-ebcab2c24614","acronym":"","url":"https://clinicaltrials.gov/study/NCT05317078","created_at":"2022-04-07T12:57:14.157Z","updated_at":"2024-07-02T16:35:23.817Z","phase":"Phase 1","brief_title":"A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications","source_id_and_acronym":"NCT05317078","lead_sponsor":"Amgen","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 expression","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 794"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 08/10/2026","primary_completion_date":" 08/10/2026","study_txt":" Completion: 02/23/2028","study_completion_date":" 02/23/2028","last_update_posted":"2024-01-11"},{"id":"cbd3eb95-a6b5-4374-a565-cf5286d2e1ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05735366","created_at":"2023-02-21T16:01:47.196Z","updated_at":"2024-07-02T16:35:29.755Z","phase":"Phase 1","brief_title":"A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05735366","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 positive","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Actemra IV (tocilizumab) • SAIL66"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-11-09"},{"id":"10310321-528e-4d9c-ac69-c830431aed02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03760081","created_at":"2021-01-18T18:28:48.728Z","updated_at":"2024-07-02T16:36:19.923Z","phase":"Phase 2","brief_title":"A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors","source_id_and_acronym":"NCT03760081","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • ASP1650"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 03/19/2019","start_date":" 03/19/2019","primary_txt":" Primary completion: 10/16/2020","primary_completion_date":" 10/16/2020","study_txt":" Completion: 10/16/2020","study_completion_date":" 10/16/2020","last_update_posted":"2021-12-02"},{"id":"d4348c92-ba91-4010-b00b-89b84a2de82c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02054351","created_at":"2021-01-18T09:26:50.599Z","updated_at":"2024-07-02T16:36:20.880Z","phase":"Phase 1","brief_title":"Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)","source_id_and_acronym":"NCT02054351","lead_sponsor":"Ganymed Pharmaceuticals GmbH","biomarkers":" MUC16 • CLDN6","pipe":"","alterations":" ","tags":["MUC16 • CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP1650"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 02/06/2014","start_date":" 02/06/2014","primary_txt":" Primary completion: 10/28/2015","primary_completion_date":" 10/28/2015","study_txt":" Completion: 10/28/2015","study_completion_date":" 10/28/2015","last_update_posted":"2021-11-10"}]